Physician profile
Christopher Michael Pieczonka
NPI 1376530121
$797,152.03
in general payments reported to CMS, 2019-2025
69 companies · $222K in 2025
The $222K reported for 2025 was more than what 99% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $84K · 2020: $64K · 2021: $70K · 2022: $103K · 2023: $136K · 2024: $117K · 2025: $222K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $254K · Consulting Fee: $169K · Travel and Lodging: $29K · Food and Beverage: $16K · Honoraria: $7,000 · Education: $430 · Gift: $16.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $253,751.42 |
| Consulting Fee | $169,411.81 |
| Travel and Lodging | $28,583.60 |
| Food and Beverage | $16,494.82 |
| Honoraria | $7,000.00 |
| Education | $430.02 |
| Gift | $16.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $208,585.44 | 2019-2025 | Carvykti, Rybrevant, Erleada |
| Bayer Healthcare Pharmaceuticals INC. | $100,693.36 | 2019-2025 | |
| Astellas Pharma US INC | $96,868.54 | 2019-2025 | Xtandi, Myrbetriq |
| Immunitybio, INC. | $76,686.95 | 2024-2025 | |
| Dendreon Pharmaceuticals LLC | $53,259.98 | 2019-2025 | Provenge |
| Myovant Sciences INC. | $36,323.14 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $34,833.29 | 2019-2025 | Yonsa |
| Merck Sharp & Dohme LLC | $31,611.60 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Pfizer INC. | $29,197.08 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $28,301.49 | 2019-2025 | Lynparza, Imfinzi, Truqap |
| Sumitomo Pharma America, INC. | $25,728.33 | 2023-2025 | Orgovyx, Gemtesa |
| Novartis Pharmaceuticals Corporation | $15,856.69 | 2023-2025 | Pluvicto |
| Boston Scientific Corporation | $12,102.26 | 2019-2025 | Spaceoar Vue System - 10ml |
| Ferring Pharmaceuticals INC. | $7,084.02 | 2019-2025 | Adstiladrin |
| Tolmar Pharmaceuticals, INC. | $6,462.24 | 2019-2022 |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eli Lilly and Company | $5,293.61 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $3,658.96 | 2020-2025 | Opdivo |
| Urogen Pharma, INC. | $3,464.85 | 2020-2025 | |
| Astrazeneca Uk Limited | $2,675.00 | 2023 | |
| Telix Pharmaceuticals | $2,173.99 | 2023-2025 | Illuccix |
| Lilly USA, LLC | $2,100.00 | 2023 | |
| Janssen Scientific Affairs, LLC | $2,097.56 | 2021-2024 | Erleada, Akeega |
| Blue Earth Diagnostics | $1,719.85 | 2021-2024 | |
| Daiichi Sankyo INC. | $1,650.00 | 2023 | |
| Exelixis INC. | $1,470.00 | 2021 | |
| Janssen Global Services, LLC | $1,436.60 | 2025 | |
| Foundation Medicine, INC. | $829.32 | 2020-2021 | |
| Myriad Genetic Laboratories, INC. | $767.73 | 2021-2025 | Prolaris |
| Accord Healthcare, INC. | $624.11 | 2022-2025 | |
| Medtronic, INC. | $599.82 | 2020-2025 | Altaviva, Interstim |
| Palette Life Sciences, INC. | $342.28 | 2021-2022 | |
| Neotract INC. | $296.17 | 2019-2020 | |
| Coloplast Corp | $262.94 | 2019-2024 | |
| Amgen INC. | $216.71 | 2019-2023 | Xgeva |
| Janssen Research & Development, LLC | $180.00 | 2023 | |
| 180 Medical, INC. | $143.81 | 2019-2023 | Gentlecath Glide |
| Histosonics, INC. | $142.42 | 2025 | |
| Procept Biorobotics Corporation | $135.75 | 2025 | |
| Siemens Medical Solutions USA, INC. | $125.28 | 2024 | Somatom Go.Top |
| Teleflex LLC | $119.49 | 2022-2023 | Urolift |
| Abbvie INC. | $117.93 | 2019-2025 | |
| Astellas Pharma Global Development | $112.64 | 2021-2025 | Xtandi, Padcev |
| C. R. Bard, INC. & Subsidiaries | $98.06 | 2019 | |
| Olympus America INC. | $85.86 | 2022-2024 | Itind System |
| Endo Pharmaceuticals INC. | $81.82 | 2022-2024 | Xiaflex, Aveed, Edex |
| Urovant Sciences INC | $80.78 | 2022 | |
| Verity Pharmaceuticals INC. | $70.25 | 2022-2025 | Trelstar |
| Antares Pharma, INC. | $53.52 | 2024 | Xyosted |
| Ethicon US, LLC | $39.94 | 2020 | |
| Endo USA, INC. | $39.41 | 2024-2025 | Aveed, Xiaflex |
| Bioprotect Medical, INC. | $31.70 | 2024-2025 | Bioprotect Balloon Implant System |
| Laborie Medical Technologies Corp. | $29.62 | 2021 | |
| Clarus Therapeutics INC. | $28.95 | 2021 | |
| Travere Therapeutics, INC. | $25.92 | 2019-2020 | |
| Dentsply Ih INC. | $22.40 | 2024 | Lofric |
| Medtronic USA, INC. | $21.70 | 2020 | |
| Genzyme Corporation | $20.42 | 2022 | |
| Bayer Healthcare LLC | $17.27 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $16.97 | 2022 | |
| Tolmar, INC. | $15.72 | 2023 | |
| Dentsply Ih Ab | $14.01 | 2023 | Lofric |
| Ambu INC. | $6.48 | 2024 |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$70,823.83 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Pieczonka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.